Skip to main content

Table 1 Characteristics of patients in the training cohort and the validation cohort

From: Nomogram-based parameters to predict overall survival in a real-world advanced cancer population undergoing palliative care

Clinicopathological features

Training cohort

Validation cohort

P value

No. of patients

247

131

 

Sex

 Male

133(53.85%)

76(58.02%)

0.4379

 Female

114(46.15%)

55(41.98%)

 

Age

 <70y

162(65.59%)

94(71.76%)

0.2222

 > = 70y

85(34.41%)

37(28.24%)

 

Tumor stage

 III

15(6.07%)

8(6.11%)

0.9895

 IV

232(93.93%)

123(93.89%)

 

Primary tumor site

 Gastrointestinal tumors

125(50.61%)

73(55.73%)

0.1352

 Thoracic cancers

66(26.72%)

20(15.27%)

 

 Urogenital neoplasms

34(13.77%)

25(19.08%)

 

 Head and neck neoplasms

10(4.05%)

6(4.58%)

 

 Other tumors

12(4.86%)

7(5.34%)

 

Concomitant disease

 No

138(55.87%)

91(69.47%)

0.0101

 Yes

109(44.13%)

40(30.53%)

 

Nutritional status

 Normal

71(28.98%)

36(27.69%)

0.7928

 Abnormal

174(71.02%)

94(72.31%)

 

Hospital stay

 <=14d

131(53.04%)

74(56.49%)

0.5215

 >14d

116(46.96%)

57(43.51%)

 

 KPS

60(10–90)

60(10–90)

0.1192

Body mass index, kg/m2

21.10(12.62–35.38)

20.80(13.67–34.05)

0.5285

Total bilirubin, umol/L

11.45(3.2–920)

11.95(2.3–389.3)

0.7913

Alkaline phosphatase, U/L

122.15(39.8–2116.1)

120.85(37.1–1342.6)

0.4955

ALT, U/L

17.85(5–914.2)

19.15(5–1156)

0.9394

AST, U/L

25.25(4.9–2435.5)

28.55(8.6–1041.4)

0.9627

Lactate dehydrogenase, U/L

234(81–2651)

217(85–2101)

0.4242

Cystatin-C, mg/L

1.25(0.65–5.7)

1.135(0.57–4)

0.0218

Creatinine, umol/L

67(26–468)

63(32–406)

0.1013

Platelet count, No. × 109/L

217(10–872)

201.5(26–753)

0.1819

Neutrophil count, No. × 109/L

6.2(1–91.7)

5.55(1.2–96)

0.0535

Lymphocyte count, No. ×109/L

1.1(0.1–32.1)

1.1(0.3–4.2)

0.6950

Hemoglobin, g/L

107(42–169)

109.5(32–171)

0.5162

CEA, ng/ml

4.76(0.32–929.1)

3.83(0.44–975.1)

0.4807

Albumin, g/L

33.6(17.3–48.4)

34.5(13.5–48.4)

0.1863

Uric acid, umol/L

314.5(71.0–1560.0)

323(70–1073)

0.6762

  1. Abbreviation: KPS karnofsky performance status score, CEA carcinoembryonic antigen, ALT Glutamic-pyruvic transaminase, AST Glutamic-oxalacetic transaminase